McElwain T J, Gore M E, Meldrum M, Viner C, Judson I R, Malpas J S
Royal Marsden Hospital, London, UK.
Bone Marrow Transplant. 1989 Dec;4 Suppl 4:109-12.
Fifty previously untreated patients with myeloma were entered into a 2-phase treatment programme: vincristine, adriamycin and methyl prednisolone (VAMP) followed by high dose intravenous melphalan (HDM) with autologous bone marrow transplantation where possible. The complete remission rate of 50% was associated with very good quality of life and the reversal of humoral immunosuppression. Complete remission is important in younger patients with myeloma as it represents a first step in achieving long, symptom- free survival.
